|
| Study information | Year | Country | Cancer type | Total number of cases (M/F) | Age distribution | Primary treatment | Cutoff value | Cutoff selection | Stage | End point | Analytic method | Follow-up interval | NOS |
|
| Zheng Y-training cohort [11] | 2019 | China | UTUC | 259 (185/74) | Mean: 67.5 years | With surgery | 1.36 | ROC analysis | Nonmetastatic | OS, CSS, MFS | Multivariate | Median 33.3 (IQR:15.5-64.2) months | 8 |
| Zheng Y-validation cohort [11] | 2019 | China | UTUC | 274 (184/90) | Mean: 65.9 years | With surgery | 1.36 | ROC analysis | Nonmetastatic | OS, CSS, MFS | Multivariate | Median 44.9 (IQR:26.93-65.8) months | 8 |
| Li [21] | 2019 | China | NSCLC | 390 (243/147) | 224: ≤65 years; 166: >65 years | With surgery | 0.99 | ROC analysis | Nonmetastatic | OS, DFS | Multivariate | Median 50 (range 12-66) months | 8 |
| Chen [22] | 2019 | China | AEG | 302 (244/58) | Median: 63 years | With surgery | 0.68 | ROC analysis | Nonmetastatic | OS | Multivariate | Median 55 (range 4-98) months | 8 |
| Pacheco-Barcia [23] | 2019 | Spain | PC | 164 (92/72) | Median: 66 years | No surgery | 2.3 | ROC analysis | Metastatic | OS, PFS | Multivariate | Less than 60 months | 7 |
| Li S-training cohort [24] | 2019 | China | PC | 371 (224/147) | Median: 62 years | With surgery | 0.69 | ROC analysis | Nonmetastatic | OS, RFS | Multivariate | Above 60 months | 8 |
| Li S-validation cohort [24] | 2019 | China | PC | 310 (164/146) | Median: 60 years | With surgery | 0.69 | ROC analysis | Nonmetastatic | OS, RFS | Multivariate | Less than 60 months | 7 |
| Chen Z-primary cohort [10] | 2019 | China | ccRCC | 414 (257/157) | Median: 56.3 years | With surgery | 1.35 | X-tile software | Mixed | OS, CSS | Multivariate | Median 69.2 months, 1 to 151 months | 8 |
| Chen Z-validation cohort [10] | 2019 | China | ccRCC | 168 (101/67) | 65: >60 years; 103: ≤60 years | With surgery | 1.35 | X-tile software | Mixed | OS, CSS | K-M | Above 60 months | 8 |
| Chen Y-primary cohort [17] | 2018 | China | NPC | 285 (210/75) | 106: <50 years; 179: ≥50 years | No surgery | 0.84 | X-tile software | Mixed | OS | Multivariate | Above 60 months | 8 |
| Chen Y-validation cohort [17] | 2018 | China | NPC | 213 (157/56) | 86: <50 years; 127: ≥50 years | No surgery | 0.84 | X-tile software | Mixed | OS | Multivariate | Above 60 months | 8 |
| Geng Y-primary cohort [18] | 2018 | China | ESCC | 542 (416/126) | Mean: 54 years | With surgery | 1.2 | ROC analysis | Nonmetastatic | OS | Multivariate | Above 60 months | 8 |
| Geng Y-validation cohort [18] | 2018 | China | ESCC | 374 (280/94) | Mean: 51 years | Withsurgery | 1.2 | ROC analysis | Nonmetastatic | OS | Multivariate | Above 60 months | 8 |
| Li S-primary cohort [20] | 2017 | China | GC | 455 (321/134) | Mean: 57.6 years | With-surgery | 0.82 | ROC analysis | Non-metastatic | DSS, DFS | Multivariate | Median 77.53 months (range 3.03-111.73) | 8 |
| Li S-validation cohort [20] | 2017 | China | GC | 327 (235/92) | Mean: 57.6 years | With surgery | 0.82 | ROC analysis | Nonmetastatic | DSS, DFS | Multivariate | Median 56.33 months (range 4.9-76.3) | 8 |
| Xu LT [19] | 2017 | China | HCC | 183 (155/28) | Mean: 53.7 years | No surgery | 1.05 | ROC analysis | Mixed | OS | Multivariate | Above 60 months | 9 |
| Qi Q-training set [5] | 2016 | China | PC | 177 (108/69) | Mean: 58.8 years | No surgery | 1.8 | ROC analysis | Mixed | OS, TTP | Multivariate | Less than 60 months | 8 |
| Qi Q-validation set 1 [5] | 2016 | China | PC | 321 (208/113) | Mean: 61.0 years | No surgery | 1.8 | ROC analysis | Mixed | OS, TTP | Multivariate | Less than 60 months | 7 |
| Qi Q-validation set 2 [5] | 2016 | China | PC | 76 (46/30) | Mean: 60.9 years | No surgery | 1.8 | ROC analysis | Mixed | OS, TTP | Multivariate | Less than 60 months | 7 |
|
